Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 230,790 shares of the medical research company’s stock after purchasing an additional 1,424 shares during the period. Royal London Asset Management Ltd.’s holdings in Amgen were worth $60,153,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Swedbank AB lifted its stake in Amgen by 1.1% in the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after buying an additional 5,751 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Amgen by 1,568.7% in the 3rd quarter. Quest Partners LLC now owns 1,919 shares of the medical research company’s stock worth $618,000 after acquiring an additional 1,804 shares during the period. Darwin Wealth Management LLC bought a new stake in Amgen in the 3rd quarter valued at about $219,000. Payden & Rygel boosted its stake in Amgen by 0.6% during the 3rd quarter. Payden & Rygel now owns 35,400 shares of the medical research company’s stock valued at $11,406,000 after purchasing an additional 200 shares during the period. Finally, Citizens Financial Group Inc. RI grew its position in Amgen by 4.4% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 14,844 shares of the medical research company’s stock worth $4,783,000 after purchasing an additional 626 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on AMGN. Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Piper Sandler lifted their target price on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Bank of America increased their price target on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research note on Wednesday, March 5th. UBS Group restated a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Finally, Truist Financial lowered their target price on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $314.04.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by company insiders.

Amgen Trading Down 0.2 %

NASDAQ AMGN opened at $315.04 on Friday. The firm’s 50 day moving average price is $296.17 and its two-hundred day moving average price is $299.14. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $169.24 billion, a price-to-earnings ratio of 41.73, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.